Ozempic has emerged as a lucrative weight-loss drug, generating anticipated sales of $17 billion in 2024 for its manufacturer, Novo Nordisk A/S, which is now Europe's highest-valued company. Originally developed for diabetes treatment, Ozempic's unintended weight-loss effect has attracted a wide audience. Novo Nordisk seeks to harness this momentum, with forecasts of the obesity drug market reaching $100 billion by 2030. The company is also advancing new treatments and expanding its production capacities, indicating confidence in sustained growth amidst evolving market conditions.
Ozempic has become a phenomenon, with $17 billion in sales projected for 2024, solidifying Novo Nordisk's position as a leading manufacturer in the obesity drug market.
Novo Nordisk anticipates the obesity drug market expanding to $100 billion by 2030, bolstered by strong sales and promising new treatments in the pipeline.
Collection
[
|
...
]